Search results
Results from the WOW.Com Content Network
Atomoxetine, sold under the brand name Strattera among others, is a selective norepinephrine reuptake inhibitor (sNRI) medication used to treat attention deficit hyperactivity disorder (ADHD) [12] and, to a lesser extent, cognitive disengagement syndrome (CDS). [13] [14] [15] It may be used alone or along with stimulant medication.
The use of stimulant medication for treatment of attention-deficit hyperactivity disorder (ADHD) is well-researched and considered one of the most effective treatments in psychiatry. [89] A 2015 study examined the long-term effects of stimulant medication for ADHD, and reported that stimulants are a highly effective treatment for ADHD in the ...
Attention deficit hyperactivity disorder management options are evidence-based practices with established treatment efficacy for ADHD.Approaches that have been evaluated in the management of ADHD symptoms include FDA-approved pharmacologic treatment and other pharmaceutical agents, psychological or behavioral approaches, combined pharmacological and behavioral approaches, cognitive training ...
ADHD medication tied to 19% lower death risk. An observational study conducted in Sweden, whose results appeared in JAMA in March 2024, further emphasized the positive impact of ADHD medication on ...
Recent research has found that high-dose prescription amphetamines, often used to treat ADHD, are linked to a seriously heightened risk of psychosis. High-dose ADHD drugs linked to 81% higher ...
Stimulant medications and certain therapies are more effective in treating ADHD symptoms than placebos, a new study on more than 14,000 adults has found.
The DSM-IV criteria for diagnosis of ADHD is 3–4 times more likely to diagnose ADHD than is the ICD-10 criteria. [210] ADHD is alternately classified as neurodevelopmental disorder [211] or a disruptive behaviour disorder along with ODD, CD, and antisocial personality disorder. [212] A diagnosis does not imply a neurological disorder. [183]
A meta-analysis of the global prevalence of ADHD in adults, published in 2021, estimated a collective prevalence of persistent adult ADHD of 2.58% globally in 2020. [4] Persistent adult ADHD is defined as meeting diagnostic criteria for ADHD in adulthood with the additional requirement of a confirmed childhood diagnosis. [4]